Coughlin Timothy 4

What Happened Timothy Coughlin, a director of Travere Therapeutics (TVTX), reported a sale of 3,250 shares on 2026-05-15. The shares were sold at $43.49 per share for a total transaction value of approximately $141,343. This was a sale (not a purchase) and is often considered a routine disposition rather than a bullish signal.

Key Details

• Transaction date: 2026-05-15
• Price: $43.49 per share
• Shares sold: 3,250
• Total value: ~$141,343
• Filing date (Form 4): 2026-05-19 (reporting the 2026-05-15 transaction)
• Shares owned after transaction: not provided in the excerpt of this filing
• Footnote: Sale was made pursuant to a written Rule 10b5-1(c) trading plan adopted on November 19, 2025

Context A 10b5-1 plan indicates the sale was prearranged under a written plan that can provide an affirmative defense against insider trading claims; it does not necessarily reflect the insider’s current view of the company. No other derivative, gift, or option-exercise activity is reported in this filing. Check the full SEC Form 4 for complete ownership figures and any additional filings for related transactions.